Compare SIEB & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SIEB | PLRX |
|---|---|---|
| Founded | 1886 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.0M | 65.6M |
| IPO Year | 1996 | 2020 |
| Metric | SIEB | PLRX |
|---|---|---|
| Price | $1.67 | $1.05 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | 14.4K | ★ 568.8K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $94,202,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.28 | N/A |
| 52 Week Low | $1.53 | $1.03 |
| 52 Week High | $4.15 | $1.95 |
| Indicator | SIEB | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.53 | 39.26 |
| Support Level | $1.55 | N/A |
| Resistance Level | $1.75 | $1.38 |
| Average True Range (ATR) | 0.06 | 0.03 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 63.68 | 23.53 |
Siebert Financial Corp is a diversified financial services firm engaged in providing brokerage and financial advisory services. The coperates through two segments: Financial Services and Media, Sports and Entertainment. The Financial Services segment mainly operates as a securities broker-dealer and provides brokerage, custody, and clearing services for retail accounts, as well as insurance and advisory services, principal and proprietary trading, market making, securities lending, and investment banking and capital markets services. The Media, Sports and Entertainment segment is engaged in the production and distribution of music and media content, as well as talent management and sports representation. It generates the majority of its revenue from the Financial Services segment.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.